News | May 02, 2026
Merck posts mixed Q1 2026 results as blockbuster drugs drive growth
But acquisition charges drag earnings into loss
But acquisition charges drag earnings into loss
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Union health minister urges graduates in Chandigarh to combine technological excellence with compassion in medical practice
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
Subscribe To Our Newsletter & Stay Updated
